Navigation Links
Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
Date:10/1/2007

PITTSBURGH, Oct. 1 /PRNewswire/ -- Cellumen, Inc. and Mayo Foundation for Medical Education and Research announced today the formation of a collaboration to apply cellular systems biology (CSB(TM)) profiling to breast cancer patient stratification. The goal is to create a breast cancer patient profile test to improve diagnosis and treatment for individualized medicine.

"We are very pleased to initiate an exciting research and development program with Mayo, a leader in individualized medicine," stated D. Lansing Taylor, Ph.D., CEO of Cellumen. "We are treating breast tumors as a 'system' within the breast cancer patient. A combination of breast cancer biomarkers and migratory immune cell biomarkers are being multiplexed in tissue micro-array (TMA) samples.

"We are enthusiastic about the synergy between Cellumen and Mayo in approaching this challenging opportunity," stated Taylor, "Mayo has great expertise and experience that will be applied to this collaboration. Cellumen continues to develop collaborations with the best in class partners to bring CSB solutions to the market."

About Cellumen

Cellumen, Inc. is the Cellular Systems Biology Company. Cellumen focuses on the cell as an integrated and interacting network of genes, proteins and metabolites responsible for normal and abnormal (disease) function. To promote efficient drug discovery and development, the company offers solutions to the dual challenges of efficacy and toxicity. The company's products and services have application in each of the major segments of the pharmaceutical pipeline: drug discovery ("cellular models of disease"), drug development ("cytotoxicity profiling") and clinical trials ("patient sample profiling"). The Cellumen team leverages its experience and expertise in High Content Screening, cell- based assays, advanced reagents and bioinformatics to create high value solutions. http://www.cellumen.com.


'/>"/>
SOURCE Cellumen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Strandware Founder Establishes Consulting Firm
2. RedPrairie Establishes Asia-Pacific Headquarters in Shanghai
3. West Coast VC Establishes Midwest Presence in Madison
4. Regional collaboration is key to states future
5. Cieslewicz, Barrett talk economic collaboration
6. Congress passes bill to ease researchers collaboration worries
7. Economic collaboration in Denver sets tall goal for Wisconsin
8. Better collaboration urged to further Wisconsin biotech
9. Southeastern Wisconsin Technology Collaboration
10. Big collaboration links learners to science on a tiny scale
11. UW-Madison releases open 3D collaboration environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):